Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Janssen Expand siRNA Delivery Collaboration

Premium

Cenix BioScience said this week that it has signed a collaboration and technology license agreement with Belgium-based Janssen Research and Development to co-develop Cenix's DARE siRNA delivery technology to improve the in vivo applicability of experiments that use the gene-silencing molecules.

According to Cenix, the deal represents an expansion of an ongoing partnership with Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

Cenix noted that certain of the technologies developed through the arrangement are expected to be useful for therapeutic siRNA delivery, as well, and will be fully owned by Cenix.

Specific terms of the arrangement were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.